Hepko-V5 (hepcortespenlisimut-L) / Immune Network - LARVOL DELTA

Strategies employed to evade the host immune response and the mechanism of drug resistance in Mycobacterium tuberculosis: In search of finding new targets. (PubMed, Curr Pharm Biotechnol) - "This article provides an in-depth and critical analysis of various strategies employed by the drug-resistant M. tuberculosis to escape the host immune response, as a result of which this bacterium persists in the host for a longer period of time and leads to the development of tuberculosis infection. Furthermore, we also discussed the new targets for the effective treatment of drug resistant tuberculosis."

Journal • Infectious Disease • Pulmonary Disease • Respiratory Diseases • Tuberculosis

Immunitor publishes interim results from phase III trial of oral immunotherapy for liver cancer (PRWeb) - P3, N=120; NCT02232490; Sponsor: Immunitor LLC; "Anti-HCC property of V5 was discovered accidentally ten years ago during clinical use for original primary indications, which are chronic viral hepatitis and liver cirrhosis. V5 has been used by over 30,000 individuals since 2002 and has never been reported of causing any serious adverse reactions."

P3 data